Liquidia Analysts Boost Their Forecasts After Q4 Earnings

Benzinga

03/07

Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.

The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”

Liquidia shares gained 4.5% to trade at $36.08 on Friday.

These analysts made changes to their price targets on Guidewire Software following earnings announcement.

HC Wainwright & Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.
Wells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.

Considering buying LQDA stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2617690631"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617690631\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617690631?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617690631","market":"hk","top_or_hot":-1,"title":"Liquidia Analysts Boost Their Forecasts After Q4 Earnings","media":"Benzinga","content":"<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”</p>\n<p>Liquidia shares gained 4.5% to trade at $36.08 on Friday.</p>\n<p>These analysts made changes to their price targets on <a href=\"https://laohu8.com/S/GWRE\">Guidewire Software</a> following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"503\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141.png 1235w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Analysts Boost Their Forecasts After Q4 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Analysts Boost Their Forecasts After Q4 Earnings\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-03-07 00:17</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>Liquidia Corp</strong> (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.</p>\n<p>The company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.</p>\n<p>Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.”</p>\n<p>Liquidia shares gained 4.5% to trade at $36.08 on Friday.</p>\n<p>These analysts made changes to their price targets on <a href=\"https://laohu8.com/S/GWRE\">Guidewire Software</a> following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.</li>\n</ul>\n<p><strong>Considering buying LQDA stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"503\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-1024x503.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/06111615/image-141.png 1235w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51101305/liquidia-analysts-boost-their-forecasts-after-q4-earnings","article_id":"2617690631","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617690631","pubTimestamp":1772813851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating expectations. Analysts have mixed opinions on stock.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"Liquidia分析师在第四季度财报公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"Liquidia Corp (NASDAQ:LQDA) reported mixed results for the fourth quarter on Thursday.\nThe company posted quarterly earnings of 15 cents per share which missed the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $92.021 million which beat the analyst consensus estimate of $83.634 million.\nDr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, 「As we close 2025, we are encouraged by how quickly YUTREPIA® has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled and systemic prostacyclin therapies.」\nLiquidia shares gained 4.5% to trade at $36.08 on Friday.\nThese analysts made changes to their price targets on Guidewire Software following earnings announcement.\n\nHC Wainwright & Co. analyst Andrew S. Fein maintained Liquidia with a Buy and raised the price target from $50 to $55.\nWells Fargo analyst Benjamin Burnett maintained the stock with an Overweight rating and raised the price target from $31 to $44.\n\nConsidering buying LQDA stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}